HUP0500842A2 - Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra - Google Patents

Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra

Info

Publication number
HUP0500842A2
HUP0500842A2 HU0500842A HUP0500842A HUP0500842A2 HU P0500842 A2 HUP0500842 A2 HU P0500842A2 HU 0500842 A HU0500842 A HU 0500842A HU P0500842 A HUP0500842 A HU P0500842A HU P0500842 A2 HUP0500842 A2 HU P0500842A2
Authority
HU
Hungary
Prior art keywords
parenteral administration
pharmaceutical
dronedarone
composition
dronedarone composition
Prior art date
Application number
HU0500842A
Other languages
English (en)
Inventor
Frédérique Bourriague-Seve
Thierry Breul
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of HUP0500842A2 publication Critical patent/HUP0500842A2/hu
Publication of HU229372B1 publication Critical patent/HU229372B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

A találmány tárgya parenterális adagolásra alkalmas gyógyászatikészítmény, amelyre jellemző, hogy hatóanyagként dronedaront vagyannak egy gyógyászatilag elfogadható sóját; fiziológiailag elfogadhatópufferoldatot, amely a készítmény pH-ját 3 és 5 közötti értéken képestartani; és fiziológiailag elfogadható, vízoldható b-ciklodextrin-származékot tartalmaz.
HU0500842A 2000-12-11 2001-12-10 Pharmaceutical dronedarone composition for parenteral administration HU229372B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0016071A FR2817750B1 (fr) 2000-12-11 2000-12-11 Composition pharmaceutique de dronedarone pour administration parenterale
PCT/FR2001/003903 WO2002047660A1 (fr) 2000-12-11 2001-12-10 Composition pharmaceutique de dronedarone pour administration parenterale

Publications (2)

Publication Number Publication Date
HUP0500842A2 true HUP0500842A2 (hu) 2005-12-28
HU229372B1 HU229372B1 (en) 2013-11-28

Family

ID=8857483

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500842A HU229372B1 (en) 2000-12-11 2001-12-10 Pharmaceutical dronedarone composition for parenteral administration

Country Status (31)

Country Link
US (1) US6939865B2 (hu)
EP (1) EP1343473B1 (hu)
JP (1) JP4399161B2 (hu)
KR (1) KR100849758B1 (hu)
CN (1) CN1235566C (hu)
AR (1) AR031649A1 (hu)
AT (1) ATE348599T1 (hu)
AU (2) AU2002217229B2 (hu)
BG (1) BG66187B1 (hu)
BR (1) BR0116060B1 (hu)
CA (1) CA2427375C (hu)
CZ (1) CZ297788B6 (hu)
DE (1) DE60125411T2 (hu)
EA (1) EA005314B1 (hu)
FR (1) FR2817750B1 (hu)
HK (1) HK1055906A1 (hu)
HU (1) HU229372B1 (hu)
IL (2) IL155428A0 (hu)
IS (1) IS2349B (hu)
MA (1) MA26969A1 (hu)
ME (2) MEP20408A (hu)
MX (1) MXPA03005221A (hu)
NO (1) NO332294B1 (hu)
NZ (1) NZ525661A (hu)
OA (1) OA12416A (hu)
PL (1) PL199846B1 (hu)
RS (1) RS50348B (hu)
SK (1) SK287115B6 (hu)
TW (1) TWI246926B (hu)
WO (1) WO2002047660A1 (hu)
ZA (1) ZA200303406B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800177A (en) * 2006-02-14 2008-01-01 Wyeth Corp Aqueous pharmaceutical formulations of ERβ selective ligands
GB0719180D0 (en) 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
AR072950A1 (es) 2008-04-17 2010-10-06 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN102342907A (zh) 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
KR20120094557A (ko) * 2011-02-01 2012-08-27 동아제약주식회사 피에이치 비의존적 용출양상을 갖는 부정맥치료제 제제
CN102908307A (zh) * 2011-08-03 2013-02-06 天津市嵩锐医药科技有限公司 供注射用盐酸决奈达隆药物组合物及其制备方法
SG11201500123XA (en) * 2012-07-12 2015-02-27 Sanofi Sa Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea
WO2022083636A1 (zh) * 2020-10-20 2022-04-28 上海博志研新药物技术有限公司 盐酸决奈达隆药物组合物、其制备方法及应用
TW202320751A (zh) * 2021-08-16 2023-06-01 大陸商上海博志研新藥物技術有限公司 鹽酸決奈達隆注射組合物、其製備方法及應用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP2004327321A (ja) * 2003-04-25 2004-11-18 Jst Mfg Co Ltd コネクタ

Also Published As

Publication number Publication date
ATE348599T1 (de) 2007-01-15
NO20031958D0 (no) 2003-04-29
HU229372B1 (en) 2013-11-28
AU1722902A (en) 2002-06-24
BG107748A (bg) 2004-03-31
KR20030060985A (ko) 2003-07-16
AU2002217229B2 (en) 2006-05-18
IS2349B (is) 2008-04-15
FR2817750A1 (fr) 2002-06-14
CA2427375A1 (fr) 2002-06-20
CZ297788B6 (cs) 2007-03-28
PL362788A1 (en) 2004-11-02
WO2002047660A1 (fr) 2002-06-20
ME00083B (me) 2010-10-10
BR0116060B1 (pt) 2013-12-31
OA12416A (fr) 2006-04-18
DE60125411D1 (de) 2007-02-01
SK7262003A3 (en) 2004-02-03
SK287115B6 (sk) 2009-12-07
CA2427375C (fr) 2011-02-01
IS6801A (is) 2003-04-30
NZ525661A (en) 2004-11-26
BR0116060A (pt) 2004-03-02
EA005314B1 (ru) 2004-12-30
EA200300406A1 (ru) 2003-10-30
ZA200303406B (en) 2004-05-03
CN1479610A (zh) 2004-03-03
IL155428A0 (en) 2003-11-23
JP2004528277A (ja) 2004-09-16
RS50348B (sr) 2009-11-10
FR2817750B1 (fr) 2003-02-21
MEP20408A (en) 2010-06-10
PL199846B1 (pl) 2008-11-28
KR100849758B1 (ko) 2008-07-31
EP1343473B1 (fr) 2006-12-20
YU46503A (sh) 2006-08-17
US6939865B2 (en) 2005-09-06
MXPA03005221A (es) 2004-03-26
CN1235566C (zh) 2006-01-11
NO332294B1 (no) 2012-08-20
JP4399161B2 (ja) 2010-01-13
TWI246926B (en) 2006-01-11
MA26969A1 (fr) 2004-12-20
EP1343473A1 (fr) 2003-09-17
NO20031958L (no) 2003-06-11
DE60125411T2 (de) 2007-10-11
US20040044070A1 (en) 2004-03-04
BG66187B1 (bg) 2011-12-30
AR031649A1 (es) 2003-09-24
IL155428A (en) 2007-10-31
HK1055906A1 (en) 2004-01-30
CZ20031612A3 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
RS77904A (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
NO961136L (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
MEP49308A (en) Once-a-day oxycodone formulations
MY122124A (en) Solid pharmaceutical composition containing benzofurane derivatives
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
ATE541562T1 (de) Ibuprofen-suspension
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
HUP0104647A2 (hu) Hatóanyagként tilidin-mezilátot tartalmazó, szabályozott hatóanyag-leadású gyógyszerkészítmény
JP2000159790A5 (hu)
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
HUP0202324A2 (hu) Prukaloprid orális oldat
BR9708280A (pt) Compostos de inclusão de diclofenaco/gama-cd
GEP20043377B (en) Pharmaceutical Complex
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
DE69635775D1 (de) Medikament gegen pulmonale herzprobleme
BR9805026A (pt) Compostos contdndo tetrahidrolipstatina
TH45760B (th) สารละลายพรูคาโลไพรด์สำหรับการให้ทางปาก

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees